Effects of interleukin-33 on cardiac fibroblast gene expression and activity

Cytokine

Volumn 58, Issue 3, 2012, Pages 368-379

  Zhu, Jinyu ^a   Carver, Wayne ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac fibroblast; Collagen; Fibrosis; Inflammation; Interleukin 33

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELLS, CULTURED; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION; HEART; INTERLEUKINS; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

MUS; RATTUS;

EID: 84862780879     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.02.008     Document Type: Article

References (97)

1. Barringer T.A. Mediterranean diets and cardiovascular disease. Curr Atheroscler Rep 2001, 3:437-445.
2. Gradman A.H., Wilson J.T. Hypertension and diastolic heart failure. Curr Cardiol Rep 2009, 11:422-429.
3. Heeneman S., Cleutjens J.P., Faber B.C., Creemers E.E., van Suylen R.J., Lutgens E., et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 2003, 200:516-525.
4. Hess O.M., Felder L., Krayenbuehl H.P. Diastolic function in valvular heart disease. Herz 1991, 16:124-129.
5. Khan R., Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006, 118:10-24.
6. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89:265-272.
7. Burlew B.S., Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002, 27:92-98.
8. Brower G.L., Gardner J.D., Forman M.F., Murray D.B., Voloshenyuk T., Levick S.P., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30:604-610.
9. Baudino T.A., Carver W., Giles W., Borg T.K. Cardiac fibroblasts: friend or foe?. Am J Physiol Heart Circ Physiol 2006, 291:H1015-1026.
10. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
11. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176.
12. Lin E., Calvano S.E., Lowry S.F. Inflammatory cytokines and cell response in surgery. Surgery 2000, 127:117-126.
13. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
14. Curfs J.H., Meis J.F., Hoogkamp-Korstanje J.A. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev 1997, 10:742-780.
15. Kelso A. Cytokines: principles and prospects. Immunol Cell Biol 1998, 76:300-317.
16. Yndestad A., Damås J.K., Øie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007, 9:236-241.
17. Nakajima H., Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007, 142:265-273.
18. Fix C., Bingham K., Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 2011, 53:19-28.
19. Onda H., Kasuya H., Takakura K., Hori T., Imaizumi T., Takeuchi T., et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999, 19:1279-1288.
20. Baekkevold E.S., Roussigné M., Yamanaka T., Johansen F.E., Jahnsen F.L., Amalric F., et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163:69-79.
21. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989, 258:301-304.
22. Klemenz R., Hoffmann S., Werenskiold A.K. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Biochemistry 1989, 86:5708-5712.
23. Kumar S., Tzimas M.N., Griswold D.E., Young P.R. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997, 235:474-478.
24. Bergers G., Reikerstorfer A., Braselmann S., Graninger P., Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13:1176-1188.
25. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
26. Chackerian A.A., Oldham E.R., Murphy E.E., Schmitz J., Pflanz S., Kastelein R.A. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551-2555.
27. Lingel A., Weiss T.M., Niebuhr M., Pan B., Appleton B.A., Wiesmann C., et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 2009, 17:1398-1410.
28. Shah R.V., Januzzi J.L. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010, 7:9-14.
29. Pascual-Figal D.A., Ordoñez-Llanos J., Tornel P.L., Vázquez R., Puig T., Valdés M., et al. MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
30. Bhardwaj A., Januzzi J.L. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010, 10:459-464.
31. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369-26380.
32. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Nat Acad Sci USA 2008, 105:10913-10918.
33. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
34. Seki K., Sanada S., Kudinova A.Y., Steinhauser M.L., Handa V., Gannon J., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.
35. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
36. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
37. Rankin A.L., Mumm J.B., Murphy E., Turner S., Yu N., McClanahan T.K., et al. IL-33 Induces IL-13-Dependent Cutaneous Fibrosis. J Immunol 2010, 184:1526-1535.
38. Burgess M.L., Terracio L., Hirozane T., Borg T.K. Differential integrin expression by cardiac fibroblasts from hypertensive and exercise-trained rat hearts. Cardiovasc Pathol 2002, 11:78-87.
39. Diaz-Araya G., Borg T.K., Lavandero S., Loftis M.J., Carver W. IGF-1 modulation of rat cardiac fibroblast behavior and gene expression is age-dependent. Cell Commun Adhes 2003, 10:155-165.
40. Zhao C., Zha Y., Wu X., Chen L., Shi J., Cui L. The quantification of ADAMTS4 and 8 expression and selection of reference genes for quantitative real-time PCR analysis in myocardial infarction. Biomed Pharmacother 2011, 65:555-559.
41. Yndestad A., Marshall A.K., Hodgkinson J.D., Tham el L., Sugden P.H., Clerk A. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. Int J Biochem Cell Biol 2010, 42:263-272.
42. Poobalarahi F., Baicu C.F., Bradshaw A.D. Cardiac myofibroblasts differentiated in 3D culture exhibit distinct changes in collagen I production, processing, and matrix deposition. Am J Physiol Heart Circ Physiol 2006, 291:H2924-H2932.
43. Zhang X., Stewart J.A., Kane I.D., Massey E.P., Cashatt D.O., Carver W.E. Effects of elevated glucose levels on interactions of cardiac fibroblasts with the extracellular matrix. In Vitro Cell Dev Biol Anim 2007, 43:297-305.
44. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
45. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?. Hypertension 2004, 43:739-745.
46. Bell E., Ivarsson B., Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Nat Acad Sci USA 1979, 76:1274-1278.
47. Liang C.C., Park A.Y., Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2:329-333.
48. Rogers J.A., Fuseler J.W. Regulation of NF-kappaB activation and nuclear translocation by exogenous nitric oxide (NO) donors in TNF-alpha activated vascular endothelial cells. Nitric Oxide 2007, 16:379-391.
49. Noursadeghi M., Tsang J., Haustein T., Miller R.F., Chain B.M., Katz D.R. Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages. J Immunol Methods 2008, 329:194-200.
50. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., et al. Kanellopoulos J.IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009, 183:1446-1455.
51. Beltrán C.J., Núñez L.E., Díaz-Jiménez D., Farfan N., Candia E., Heine C., et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:1097-1107.
52. Whelan R., Kim C., Chen M., Leiter J., Grunstein M.M., Hakonarson H. Role and regulation of interleukin-1 molecules in pro-asthmatic sensitised airway smooth muscle. Eur Respir J 2004, 24:559-567.
53. Schneider E., Petit-Bertron A.F., Bricard R., Levasseur M., Ramadan A., Girard J.P., et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 2009, 183:3591-3597.
54. Moulin D., Donzé O., Talabot-Ayer D., Mézin F., Palmer G., Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007, 40:216-225.
55. Andrade M.V., Iwaki S., Ropert C., Gazzinelli R.T., Cunha-Melo J.R., Beaven M.A. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol 2011, 41:760-772.
56. Guidry C., Grinnell F. Contraction of hydrated collagen gels by fibroblasts: evidence for two mechanisms by which collagen fibrils are stabilized. Coll Relat Res 1987, 6:515-529.
57. Carver W., Molano I., Reaves T.A., Borg T.K., Terracio L. Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol 1995, 165:425-437.
58. Tingström A., Heldin C.H., Rubin K. Regulation of fibroblast-mediated collagen gel contraction by platelet-derived growth factor, interleukin-1 alpha and transforming growth factor-beta 1. J Cell Sci 1992, 102:315-322.
59. Stewart J.A., Massey E.P., Fix C., Zhu J., Goldsmith E.C., Carver W. Temporal alterations in cardiac fibroblast function following induction of pressure overload. Cell Tissue Res 2010, 340:117-126.
60. Hsueh W.A., Law R.E., Do Y.S. Integrins, adhesion, and cardiac remodeling. Hypertension 1998, 31:176-180.
61. Yagami A., Orihara K., Morita H., Futamura K., Hashimoto N., Matsumoto K., et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 2010, 185:5743-5750.
62. Yanaba K., Yoshizaki A., Asano Y., Kadono T., Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011, 30:825-830.
63. Lécart S., Lecointe N., Subramaniam A., Alkan S., Ni D., Chen R., et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002, 32:2979-2987.
64. Meisel C., Bonhagen K., Löhning M., Coyle A.J., Gutierrez-Ramos J.C., Radbruch A., et al. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001, 166:3143-3150.
65. Coyle A.J., Lloyd C., Tian J., Nguyen T., Erikkson C., Wang L., et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190:895-902.
66. Aoki S., Hayakawa M., Ozaki H., Takezako N., Obata H., Ibaraki N., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010, 335:75-81.
67. Manetti M., Ibba-Manneschi L., Liakouli V., Guiducci S., Milia A.F., Benelli G., et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010, 69:598-605.
68. Miller A.M., Liew F.Y. The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011, 131:179-186.
69. Marvie P., Lisbonne M., L'helgoualc'h A., Rauch M., Turlin B., Preisser L., et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010, 14:1726-1739.
70. Saidi S., Bouri F., Lencel P., Duplomb L., Baud'huin M., Delplace S., et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 2011, 53:347-354.
71. Chow J.Y., Wong C.K., Cheung P.F., Lam C.W. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010, 7:26-34.
72. Smithgall M.D., Comeau M.R., Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
73. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003, 149:1-38.
74. Kanda T., Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004, 45:183-193.
75. Fischer P., Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 2007, 102:279-297.
76. Siwik D.A., Chang D.L., Colucci W.S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000, 86:1259-1265.
77. Banerjee I., Fuseler J.W., Intwala A.R., Baudino T.A. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 2009, 296:H1694-1704.
78. Niu J., Kolattukudy P.E. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 2009, 117:95-109.
79. Tarzami S.T., Cheng R., Miao W., Kitsis R.N., Berman J.W. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J Mol Cell Cardiol 2002, 34:209-221.
80. Tarzami S.T., Calderon T.M., Deguzman A., Lopez L., Kitsis R.N., Berman J.W. MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway. Biochem Biophys Res Commun 2005, 335:1008-1016.
81. Dewald O., Zymek P., Winkelmann K., Koerting A., Ren G., Abou-Khamis T., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005, 96:881-889.
82. Martire A., Fernandez B., Buehler A., Strohm C., Schaper J., Zimmermann R., et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation. Cardiovasc Res 2003, 57:523-534.
83. Pecaric-Petkovic T., Didichenko S.A., Kaempfer S., Spiegl N., Dahinden C.A. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009, 113:1526-1534.
84. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780-4790.
85. Rossini A., Zacheo A., Mocini D., Totta P., Facchiano A., Castoldi R., et al. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 2008, 44:683-693.
86. Li M., Georgakopoulos D., Lu G., Hester L., Kass D.A., Hasday J., et al. P38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 2005, 111:2494-2502.
87. Frantz S., Behr T., Hu K., Fraccarollo D., Strotmann J., Goldberg E., et al. Role of p38 mitogen-activated protein kinase in cardiac remodelling. Br J Pharmacol 2007, 150:130-135.
88. Zhang W., Elimban V., Nijjar M.S., Gupta S.K., Dhalla N.S. Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp Clin Cardiol 2003, 8:173-183.
89. Sano M., Fukuda K., Sato T., Kawaguchi H., Suematsu M., Matsuda S., et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 2001, 89:661-669.
90. Hata K., Andoh A., Shimada M., Fujino S., Bamba S., Araki Y., et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002, 282:G1035-1044.
91. Tare N., Li H., Morschauser A., Cote-Sierra J., Ju G., Renzetti L., et al. KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: functional responses and identification of signaling pathways. Exp Cell Res 2010, 316:2527-2537.
92. Funakoshi-Tago M., Tago K., Sato Y., Tominaga S., Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-κB activation. Cell Signal 2011, 23:363-370.
93. Keeley E.C., Mehrad B., Strieter R.M. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011, 4:2.
94. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225:631-637.
95. Keeley E.C., Mehrad B., Strieter R.M. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb Haemost 2009, 101:613-618.
96. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779-2786.
97. Verri W.A., Souto F.O., Vieira S.M., Almeida S.C., Fukada S.Y., Xu D., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010, 69:1697-1703.